Lorlatinib in Advanced ROS1+ NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lorlatinib in Advanced ROS1-Positive Non-Small-Cell Lung Cancer: A Multicentre, Open-Label, Single-Arm, Phase 1-2 Trial
Lancet Oncol 2019 Oct 25;[EPub Ahead of Print], AT Shaw, BJ Solomon, R Chiari, GJ Riely, B Besse, RA Soo, S Kao, CC Lin, TM Bauer, JS Clancy, H Thurm, JF Martini, G Peltz, A Abbattista, S Li, SI OuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.